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Key messages
What is already known about this subject?
 ► Though diabetic ketoacidosis (DKA) audits have re-
sulted in a transitory improvement in its manage-
ment, continuous and ongoing improvement has 
been difficult to establish.
What are the new findings?
 ► We were able to reduce DKA duration with tailored 
interventions and sustain the improvement with 
regular feedback. The trend of DKA duration headed 
toward baseline in the absence of regular feedback.
How might these results change the clinical 
practice?
 ► Incorporating regular feedback to end users may 
help provide better care to patients with DKA.
AbstrAct
Objectives We postulate that performance feedback is a 
prerequisite to ensure sustained improvement in diabetic 
ketoacidosis (DKA) management.
Design The study was based on ‘theory of change’ 
concept that suggests changes of primary drivers 
determine the main outcome. A set of secondary drivers 
can be implemented to achieve improvements in these 
primary drivers and thus the main outcome.
Setting This study was conducted at a large tertiary care 
center in the West Midlands, UK. The region has above 
average prevalence of diabetes and DKA admissions in the 
country.
Participants All participants diagnosed with DKA as per 
national guidelines, except those managed in intensive 
care unit from April 2014 to March 2018, were included in 
this study.
Interventions Monthly feedback of performance was 
the main intervention. Development of a real-time live 
DKA audit tool, automatic referral system of DKA to 
the specialist team, electronic monitoring of blood gas 
measurements and education and redesigning of local 
(trust) guidelines were the other interventions in this study.
Main outcome measures Total DKA duration, 
appropriateness of fixed rate intravenous insulin infusion, 
fluid prescription, glucose monitoring, ketone monitoring 
and referral to specialists.
Results There was a significant reduction in the duration 
of DKA postintervention compared with baseline results. 
However, in the absence of regular feedback, the duration 
of DKA showed an upward trend nearing baseline values. 
Similar trends were noted in secondary drivers influencing 
DKA duration.
Conclusion Based on these results, we recommend 
regular audit and feedback is required to sustain 
improvements in DKA management.
PRObleM
Diabetic ketoacidosis (DKA) is an acute endo-
crine emergency requiring rapid assessment and 
treatment.1 The Joint British Diabetes Societies 
produced guidance standardizing DKA manage-
ment for inpatients in 2010 and subsequently 
revised them in 2013.2 These guidelines served 
as the standard for several audits conducted 
at our institution. Though these audits may 
have resulted in a transitory improvement in 
DKA management, continuous and ongoing 
improvement in DKA management was difficult 
to establish. Ivers et al3 reported that feedback of 
audit generally induces small improvement in 
clinical practice, but a professional behavioral 
change is best brought about by the combina-
tion of continuous education, feedback and 
auditing.4–7 We previously reported that our 
interventions using the plan–do–study–act cycle 
reduced the mean duration of DKA from 22.0 
to 10.2 hours.8 9 We hypothesize that perfor-
mance feedback is required to ensure sustained 
improvement in DKA management and that 
loss of this feedback would lead to a longer 
duration of DKA.
baCkgROunD
DKA is characterized by the triad of hypergly-
cemia (blood glucose >11 mmol/L), acidosis 
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Figure 1 Six distinctive time periods of the study.
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(pH <7.3 or bicarbonate <15 mmol/L) and ketogenesis 
(serum ketones>3 mmol/L).2 10 11 Although mediated 
primarily by insulin deficiency (relative or absolute), it 
can be precipitated by systemic disease, non-compliance 
with treatment, or previously undiagnosed disease.11 The 
prevalence of DKA varies with regions: 50–100 per 1000 
in the USA,12–14 103–128 per 1000 in Canada15 16 and 39 
per 1000 in patients with type 1 diabetes in Germany and 
Austria.17 In their recent study, Fazeli Farsani et al18 have 
summarized the incidence and prevalence of DKA in 
various regions of the world.
While prevalence rates of DKA in the UK are currently 
unavailable, incidence data of DKA in the UK has 
improved from 51.3 per 1000 person-years to 8 per 1000 
person-years.19 20 It should be noted these are single-
center reports based on patient medical records. In 2019, 
an estimated 9.5% of the population in the West Midlands 
had diabetes, compared with the rest of the UK popu-
lation (8.7%).21 General practice data from 2016/2017 
revealed that Birmingham has an high prevalence rate of 
diabetes mellitus.22 We currently have over 100 000 emer-
gency admissions a year, of which 20.89% have diabetes.23
About 10% of people with diabetes have type 1 
diabetes.24 A proportion of this population (45.9% in 
2015) were admitted to a hospital with DKA. More alarm-
ingly, there is an unchanging incidence (about 4%) of 
patients with type 1 diabetes inpatients that developed 
DKA during their hospital stay.24 This underlines the need 
to identify key drivers to enhance DKA management.
Measurement, design and strategy
This study was conducted at the Queen Elizabeth 
Hospital Birmingham, part of the University Hospitals 
Birmingham National Health Service (NHS) Foundation 
Trust. As one of the busiest NHS organizations, it saw 
more than 135 000 inpatient episodes and over 115 000 
emergency department attendances (~315 patients, 
daily) over the course of 2016/2017.25
All patients diagnosed with DKA as per national guide-
lines from April 2014 to September 2018 were included 
in this study. Those patients managed in intensive care 
unit were excluded to avoid bias resulting from person-
alized and one-to-one care. Results showing improve-
ment in DKA duration up to September 2016 following 
certain interventions have been previously reported.8 9 
We have further divided the entire study into six distinc-
tive time periods (figure 1). The study was based on the 
‘theory of change’ concept that suggests the changes 
of primary drivers determine the main outcome.26–29 A 
set of secondary drivers were implemented to achieve 
improvements in these primary drivers and thus the main 
outcome. Therefore, the measurement of the primary 
drivers in their own entity is an overall measurement of 
the principal outcome.
Results from the initial retrospective audit from April 
2014 to September 2014 were presented to frontline staff 
involved primarily in the initiation of DKA management 
(emergency, acute and diabetes teams). From the ensuing 
discussion, the main outcome of a reduction in DKA 
duration by 50% within the first 12 hours of the diagnosis 
of DKA was established. The process of choosing primary 
and secondary drivers is graphically described in figure 2. 
As previously described,9 the primary outcome was tested 
by five main interventions (secondary drivers) through 
the plan–do–study–act (PDSA) method:
1. Development of a real-time live audit tool:. This inter-
vention led to the generation of a real-time audit tool 
that shortens the delay between data collection and 
propagation of the analyzed results. We used the ex-
isting Prescribing Information and Communications 
System (PICS) to capture observations, prescribing 
and referral requests. This system has enabled the 
timely monitoring of glucose and ketone measure-
ments, prescription of fluids and insulin, and specialist 
referrals.
2. An automatic referral system to the specialist team: 
The prescription of a fixed rate intravenous insulin in-
fusion (FRIII) on PICS triggers an automated referral 
to the diabetes team.
3. Electronic monitoring of blood gas measurements:. 
Before this intervention, point-of-care blood gas ana-
lyzer results were not part of our electronic observa-
tion system. Since the incorporation of these results 
onto PICS, it has allowed for electronic and remote 
monitoring of pH, blood glucose and ketone measure-
ments accurately.
4. Education and redesigning of local (trust) guidelines. 
A simplified ‘A to K & D’ DKA trust guideline was de-
signed and made accessible through the intranet and 
as posters in the emergency and acute medicine floors.
5. Monthly feedback: Monthly audits of the primary driv-
ers were presented to the frontline teams.
Interlink between the primary and secondary drivers 
with the main outcome of DKA duration is represented 
in figure 3. The newly improved one-page DKA protocol 
with mnemonic introduced as part of this study is repre-
sented in figure 4. The performance of the key drivers that 
influence DKA duration (appropriateness of FRIII, fluid 
prescription, glucose monitoring, ketone monitoring 
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Figure 2 Several factors underlie the primary drivers that overall influenced the main outcome of DKA duration. The lower half 
of the figure describes the timeline of various interventions (secondary drivers) during the QIP. DKA, diabetic ketoacidosis. ED, 
emergency department; CDU, clinical decision unit; QIP, quality improvement project.
Figure 3 Five (numbered) primary and secondary 
(yellow) divers. (1) Fluid replacement is the most vital initial 
management step. Guidelines recommend at least 4 L 
of fluid replacement within the first 12 hours (1000 mL in 
the first hour, 2000 mL over the next 4 hours and 8 hours, 
respectively). (2) Fixed rate intravenous insulin infusion (FRIII) 
will switch lipolysis off, thereby disinitiating the metabolic 
acidosis induced by DKA. It is recommended that 0.1 units/
kg body weight of FRIII be used. (3) Initiation of FRIII will 
cause the glucose to fall sharply, and as such, hourly glucose 
measurement is mandatory. Further glucose infusions may 
be required in the latter stages of DKA management to 
avoid hypoglycemia until ketogenesis is switched off. (4) 
The recommendation is for hourly ketone measurement 
and aiming for insulin titration to reduce blood ketones by 
0.5 mmol/L/hour. (5) Patients with DKA should be referred to 
the specialist diabetic team on admission or early specialist 
input. Secondary interventions in our QIP included: (A) the 
development of a real-time audit tool; (B) automatic referral 
system; (C) electronic blood gas monitoring; (D) monthly 
feedback; and (E) education and redesigning of local 
guidelines. DKA, diabetic ketoacidosis.
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and referral to specialists) were presented to our liaison 
consultants in the frontline team who then cascaded the 
results to the rest of their team. The frontline team in our 
hospital consists of members of the emergency medical 
team and the acute medical team. In our DKA pathway, 
patients would be first assessed in the emergency depart-
ment where the diagnosis of DKA would be confirmed 
and treatment initiated. Once stabilized, the patient 
would subsequently be transferred to our acute medical 
unit where they would be managed until DKA resolution. 
One of the authors regularly met the liaison consult-
ants in person during this process to ensure a two-way 
communication so that factors that influenced that 
month’s results could be learnt and required interven-
tions were initiated in the following months to improve 
the performance of key drivers. Such feedback continued 
until September 2016. We then studied the effect of not 
having the monthly feedback to the frontline teams from 
October 2016 to March 2018.
ReSulTS
A total of 432 DKA episodes were included in the study. 
table 1 describes the baseline characteristics of the study 
population throughout each year of the study with the 
breakdown of DKA admissions contributing to the study. 
There were a significantly lower number of DKA admis-
sions in the follow-up period despite no change in the 
eligibility criteria of enrolling DKA admissions to the 
study. figure 5 reports our primary outcome measure 
that was the duration of time patients were in DKA. When 
continuous feedback was in place, there was a signifi-
cant reduction in the duration of DKA postintervention 
(p<0.001). However, in the absence of regular feedback 
from September 2016 onward, the duration of DKA 
showed an upward trend. Yet, the median DKA duration 
in the post follow-up period remained significantly lower 
compared with the preintervention period. Further 
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Figure 4 The revised one-page DKA protocol with easy to remember mnemonic introduced as part of the intervention in the 
QIP. DKA, diabetic ketoacidosis.
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details of the median values of change are described in 
table 1.
Appropriateness of FRIII, fluid prescription, glucose 
monitoring and ketone monitoring is described in 
figure 6. Following our interventions, we successfully 
reduced the dispersion values for FRIII—up to 92% 
of the values were within 20% of the guideline value. 
The effect persisted in the post follow-up periods; the 
values became less dispersed and showed a continu-
ally improving prescribing practice. The proportion of 
patients receiving recommended fluids improved in the 
period of regular feedback. However, this became more 
variable during the post follow-up period. While the 
dispersion of glucose measurement frequency improved 
with regular feedback, the trend towards increased moni-
toring was noted after feedback was stopped. A signifi-
cant increase in ketone monitoring was noted in the 
latter periods of the study. Although there was more 
appropriate ketone testing following our interventions, 
the trend diverted toward the opposite axis indicating an 
unnecessary use of resources.
lessons and limitations
In this study, we demonstrate a significant and sustained 
reduction in DKA attributable to the ‘theory of change’ 
model of quality improvement. Furthermore, the absence 
of regular performance feedback (secondary drivers) in 
the post follow-up period was associated with a greater 
degree of deviation from treatment guidelines and 
longer DKA duration. Although we cannot conclude with 
certainty that the lack of feedback was the sole reason 
for worsening DKA duration, we observed a strong rela-
tionship between regular feedback and DKA duration. 
Conversely, we also recognized that withdrawal of the 
regular feedback mechanism, even if not strictly causal, 
has resulted in an increase in DKA duration.
Improvements need to continue to ensure the best 
quality of care and patient safety within the NHS. While 
simple audits have been useful in assessing adherence to 
guidelines,30 they have their limitations. A recent review 
of assessing the impact of healthcare interventions using 
routine data by Clarke et al31 outlines these points. We 
demonstrate the utility of the PDSA model to improve 
clinical care in DKA management. We have gone further 
and demonstrated that key to the sustainability of 
improved outcomes relies on regular feedback. Ideally, 
we would have collected data using more prospective 
methodology. However, lack of resources restricted the 
span of our data collection. Nevertheless, the deteriora-
tion in DKA duration with concomitant lack of feedback 
mechanism is noticeable and statistically significant.
Duration of DKA is multifactorial and relates to the 
underlying cause of DKA, timely diagnosis, quick and 
appropriate treatment and monitoring. This is in turn 
dependent on the knowledge of nursing and medical 
staff and approach of the diabetes specialist team. We 
initially tried to measure the baseline knowledge, attitude 
and practices for DKA among frontline staff in the emer-
gency department and acute medical unit. However, we 
found it challenging to update the constantly changing 
junior doctors in training rotations. Furthermore, we also 
noted a higher turnover of nursing and allied medical 
health staff in these departments compared with the rest 
of the hospital. Following this, we established a liaison 
consultant in these departments through whom we 
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Figure 5 Duration of DKA per year. DKA, diabetic 
ketoacidosis.
Figure 6 Appropriateness of fixed rate intravenous insulin infusion prescription, fluid prescription, glucose monitoring and 
ketone monitoring. It represents the dispersion of each measure from the baseline recommendation. For example, the standard 
recommendation for FRIII rate for a patient weighing 60 kg is 6 units/hour (0.1 unit × weight of the patient). A prescription of 
6 units/hour would register at ‘0’ on the y-axis, whereas a prescription of 3 and 9 units for the same patient would register at 
−50% and 50%, respectively.
Epidemiology
disseminated the results of performance indicators for 
DKA and suggested necessary improvements that were to 
be delivered at the department level. We aim to capture 
such interventions in our future updated study.
While the DKA duration is important, complications 
such as hypokalemia and hypoglycemia resulting from 
the management of DKA could be life threatening.32–35 
The initial hyperglycemia and metabolic acidosis result 
in a relatively higher serum osmolarity, which then 
induces osmotic diuresis and renal electrolyte loss, potas-
sium being the most significant. Vomiting, a commonly 
associated symptom in DKA, results in further potas-
sium loss.36 With treatment initiation and insulin infu-
sion, there is a shift of potassium from serum into cells 
further exaggerating the hypokalemia. Several cases of 
profound hypokalemia leading to cardiac dysrhythmias 
have been reported in the past.37–39 Hypoglycemia is the 
most frequent complication with DKA treatment arising 
secondary to the discrepancy between the availability of 
glucose to insulin that that needs to switch off lipolysis.32 
Lately, there is an increased frequency of euglycemic 
ketoacidosis associated with sodium-glucose cotrans-
porter-2 (SGLT2) inhibitors. Such patients with SGLT2 
inhibitor associated euglycaemic ketoacidosis are more 
susceptible to hypoglycemia with DKA treatment further 
to a complex drug-associated mechanism.40 However, 
there is limited literature studying the prevalence and 
associated risk factors of hypoglycemia resulting from 
DKA treatment.
Regrettably, we did not measure these complications 
in this study. Therefore, we cannot ascertain if our inter-
vention made any difference to these complication rates. Protected by copyright.
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Moreover, we were not able to assess if a shorter duration 
of DKA influences readmission rates. We are currently in 
the process of updating our DKA monitoring system to 
include monitoring for hypokalemia and hypoglycemia 
alongside the time of administration of basal insulin 
during each episode. Frequencies of recurrent DKA 
admission and its causal factors have been proposed 
as further parameters that warrant monitoring. We 
excluded patients who were managed in intensive care 
as the benefit of continuous monitoring and one-to-one 
nursing could impact patients’ management. Further 
research is needed to study the specifics (impact of 
timing, dose and administration of long-acting insulin) 
on DKA duration and the global management of DKA.
COnCluSIOn
In this study, we demonstrated that regular audit and 
feedback is required to sustain improvements in DKA 
management. We hope to implement further audit cycles 
into our service development to continue data collection 
and reduce DKA duration. Further studies are needed to 
assess the reproducibility and validity of these findings in 
larger and diverse settings.
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